Surgical Treatment of Gynecomastia
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 1.129 alerts
Get alerted when Policy MP 1.129 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage determinations for surgical removal of breast tissue (excision or liposuction) to treat gynecomastia for members in applicable Capital BlueCross products; it explains the payer's stance that these procedures are investigational due to insufficient evidence of functional benefit.
Surgery for gynecomastia changed from medically necessary to investigational.
Coverage Determination for Surgical Treatment of Gynecomastia
Investigational / Not Covered Criteria
Surgical removal of breast tissue for gynecomastia
Based on absence of randomized controlled trials and limited nonrandomized evidence; conservative therapies (treatment of underlying hormonal disorder, cessation of offending drugs, weight loss) often address symptoms and gynecomastia frequently resolves spontaneously, particularly in adolescents.
Surgical removal of breast tissue (including mastectomy or liposuction) for the treatment of gynecomastia is excluded from coverage and is considered investigational. This determination is based on the policy finding that there is insufficient evidence of functional impairment and insufficient evidence demonstrating meaningful health outcome benefits from these procedures for the indicated condition.
The rationale for the investigational stance is the lack of high-quality evidence demonstrating improved functional outcomes after surgical treatment. The available literature consists of nonrandomized studies only, and there are no randomized controlled trials (RCTs) addressing functional outcomes following surgery for bilateral gynecomastia. Because conservative therapy often addresses pain or discomfort and gynecomastia typically does not cause functional impairment, the evidence is insufficient to conclude that surgical intervention improves symptoms, function, or net health outcome.
Relevant Procedure and Diagnosis Codes
| 19300 | Mastectomy for gynecomastia (procedure code listed in policy as investigational) |
| N62 | Hypertrophy of breast |
Provider Responsibilities, Prior Authorization, and Claim Considerations
Prior authorization and coding note — investigational codes may affect authorization
The policy identifies specific procedure codes (for example, CPT 19300) in the “Investigational therefore not covered” coding list; identification of these codes does not guarantee coverage and coverage determinations remain subject to the member’s benefit terms and prior authorization rules.
- Example investigational procedure code listed: CPT 19300
- Code listing does not denote coverage; coverage is determined by member benefit information and contract terms
Conservative therapy expected prior to surgery
Before considering surgical removal of breast tissue, conservative management is expected — treat underlying hormonal disorders, stop offending drugs, and recommend weight loss; many cases resolve spontaneously (particularly in adolescents) and surgery may be considered only if conservative therapies are ineffective or not possible.
- Treat underlying hormonal disorder
- Cessation of offending drug therapy
- Weight loss and observation for spontaneous resolution
- Surgery considered only if conservative measures fail or are not possible
Claims processing and required documentation
Final claim payment and processing depend on the member’s benefit program, eligibility on the date of service, and a determination that services are medically necessary and appropriate; providers should be prepared to supply documentation supporting medical necessity on request.
- Payment is subject to applicable contract terms, benefit limitations, and exclusions
- Contact Provider Services or Member Services for questions about applicability to a member
Denial risk for surgical gynecomastia procedures (e.g., CPT 19300)
Claims for surgical removal of breast tissue for gynecomastia (example: CPT 19300) are listed as investigational and may be denied as not covered due to insufficient evidence of improved functional outcomes.
- Procedure code 19300 is listed in the policy’s investigational/not covered coding list
- Surgery for gynecomastia is considered investigational due to lack of demonstrated functional impairment and insufficient evidence of benefit
Clinical Background
Bilateral gynecomastia is the benign enlargement of the male breast due to increased adipose, glandular, fibrous tissue, or a combination of these tissue types. It may be associated with hormonal disorders, certain medications, obesity, or particular age-related categories (for example, neonatal, adolescent, or older adults). Many cases resolve spontaneously or respond to conservative management; persistent or long-standing gynecomastia can develop fibrosis and may be evaluated for surgical options when conservative measures fail.
Definitions
Policy Revision History
Administrative update: Removed Benefit Variations section and updated Disclaimer.
Major review: surgery for gynecomastia changed from medically necessary to investigational; Policy Guidelines removed and Background, Rationale, Benefit Variation, Disclaimer and References updated.
Consensus review with no change to policy statement; Background updated and references added.
Minor review: adolescent and adult criteria separated; criteria revised to include ASPS gynecomastia scale, removal of Tanner stage, incorporation of pain and discomfort, symptoms required to be refractory to medical treatment and persist 4–12 months; Policy Guidelines extensively revised; Background, Rationale and References updated.
Consensus review with no change to policy statement; coding reviewed and FEP updated; references updated.
Consensus review with no change to policy statement; coding reviewed and references updated.
Consensus review with no changes to policy statements; coding reviewed and references updated.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.